The main highlights for Synairgen in 2015 were the research collaboration with Pharmaxis and AstraZeneca commencing its Phase IIa trial of AZD9412 (formally SNG001). News flow from both is expected in 2017 with the former commencing clinical trials and the later announcing data. The group has also announced positive, albeit very early, data from its collaboration with Pharmaxis this morning. Synairgen continues to screen for new opportunities and expects to establish at least one in the coming y ....
